Dominari Holdings (FRA:BP2A) Debt-to-Asset : 0.06 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Dominari Holdings Debt-to-Asset?

Dominari Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.39 Mil. Dominari Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.70 Mil. Dominari Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €48.02 Mil. Dominari Holdings's debt to asset for the quarter that ended in Mar. 2024 was 0.06.

Dominari Holdings Debt-to-Asset Historical Data

The historical data trend for Dominari Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Debt-to-Asset Chart

Dominari Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.06

Dominari Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.05	0.05	0.06	0.06	0.06

Competitive Comparison of Dominari Holdings's Debt-to-Asset

For the Biotechnology subindustry, Dominari Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dominari Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Debt-to-Asset falls into.

Dominari Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Dominari Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.386	+	2.777)	/	52.781
	=	0.06

Dominari Holdings's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.385	+	2.695)	/	48.018
	=	0.06

Dominari Holdings (FRA:BP2A) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Dominari Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Dominari Holdings (FRA:BP2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (FRA:BP2A) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DOMH:USA BP2A:Germany

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Dominari Holdings (FRA:BP2A) Headlines

No Headlines